GILD 10-Q Quarterly Report March 31, 2024 | Alphaminr
ALPHAMINR

GILD 10-Q Quarter ended March 31, 2024

Balance Sheet
Cash Flow
Income Statement
Debt
GILEAD SCIENCES INC
10-Ks and 10-Qs
10-Q
 		Quarter ended March 31, 2024
10-K
 		Fiscal year ended Dec. 31, 2023
10-Q
 		Quarter ended Sept. 30, 2023
10-Q
 		Quarter ended June 30, 2023
10-Q
 		Quarter ended March 31, 2023
10-K
 		Fiscal year ended Dec. 31, 2022
10-Q
 		Quarter ended Sept. 30, 2022
10-Q
 		Quarter ended June 30, 2022
10-Q
 		Quarter ended March 31, 2022
10-K
 		Fiscal year ended Dec. 31, 2021
10-Q
 		Quarter ended Sept. 30, 2021
10-Q
 		Quarter ended June 30, 2021
10-Q
 		Quarter ended March 31, 2021
10-K
 		Fiscal year ended Dec. 31, 2020
10-Q
 		Quarter ended Sept. 30, 2020
10-Q
 		Quarter ended June 30, 2020
10-Q
 		Quarter ended March 31, 2020
10-K
 		Fiscal year ended Dec. 31, 2019
10-Q
 		Quarter ended Sept. 30, 2019
10-Q
 		Quarter ended June 30, 2019
10-Q
 		Quarter ended March 31, 2019
10-K
 		Fiscal year ended Dec. 31, 2018
10-Q
 		Quarter ended Sept. 30, 2018
10-Q
 		Quarter ended June 30, 2018
10-Q
 		Quarter ended March 31, 2018
10-K
 		Fiscal year ended Dec. 31, 2017
10-Q
 		Quarter ended Sept. 30, 2017
10-Q
 		Quarter ended June 30, 2017
10-Q
 		Quarter ended March 31, 2017
10-K
 		Fiscal year ended Dec. 31, 2016
10-Q
 		Quarter ended Sept. 30, 2016
10-Q
 		Quarter ended June 30, 2016
10-Q
 		Quarter ended March 31, 2016
10-K
 		Fiscal year ended Dec. 31, 2015
10-Q
 		Quarter ended Sept. 30, 2015
10-Q
 		Quarter ended June 30, 2015
10-Q
 		Quarter ended March 31, 2015
10-K
 		Fiscal year ended Dec. 31, 2014
10-Q
 		Quarter ended Sept. 30, 2014
10-Q
 		Quarter ended June 30, 2014
10-Q
 		Quarter ended March 31, 2014
10-K
 		Fiscal year ended Dec. 31, 2013
10-Q
 		Quarter ended Sept. 30, 2013
10-Q
 		Quarter ended June 30, 2013
10-Q
 		Quarter ended March 31, 2013
10-K
 		Fiscal year ended Dec. 31, 2012
10-Q
 		Quarter ended Sept. 30, 2012
10-Q
 		Quarter ended June 30, 2012
10-Q
 		Quarter ended March 31, 2012
10-K
 		Fiscal year ended Dec. 31, 2011
10-Q
 		Quarter ended Sept. 30, 2011
10-Q
 		Quarter ended June 30, 2011
10-Q
 		Quarter ended March 31, 2011
10-K
 		Fiscal year ended Dec. 31, 2010
10-Q
 		Quarter ended Sept. 30, 2010
10-Q
 		Quarter ended June 30, 2010
10-Q
 		Quarter ended March 31, 2010
10-K
 		Fiscal year ended Dec. 31, 2009
PROXIES
DEF 14A
 		Filed on March 28, 2024
DEF 14A
 		Filed on March 23, 2023
DEF 14A
 		Filed on March 24, 2022
DEF 14A
 		Filed on March 30, 2021
DEF 14A
 		Filed on March 24, 2020
DEF 14A
 		Filed on March 25, 2019
DEF 14A
 		Filed on March 26, 2018
DEF 14A
 		Filed on March 27, 2017
DEF 14A
 		Filed on March 28, 2016
DEF 14A
 		Filed on March 27, 2015
DEF 14A
 		Filed on March 24, 2014
DEF 14A
 		Filed on March 19, 2013
DEF 14A
 		Filed on March 20, 2012
DEF 14A
 		Filed on March 22, 2011
DEF 14A
 		Filed on March 22, 2010
TABLE OF CONTENTS
Part I. Financial InformationItem 1. Condensed Consolidated Financial StatementsItem 2. Management S Discussion and Analysis Of Financial Condition and Results Of OperationsItem 3. Quantitative and Qualitative Disclosures About Market RiskItem 4. Controls and ProceduresPart II. Other InformationItem 1. Legal ProceedingsItem 1A. Risk FactorsItem 2. Unregistered Sales Of Equity Securities and Use Of ProceedsItem 3. Defaults Upon Senior SecuritiesItem 4. Mine Safety DisclosuresItem 5. Other InformationItem 6. Exhibits

Exhibits

(1) 2.1 Agreement and Plan of Merger, dated February 11, 2024, among CymaBay Therapeutics, Inc.,Registrantand Pacific Merger Sub, Inc. (2) 3.1 Restated Certificate of Incorporation of Registrant (3) 3.2 Amended and Restated Bylaws of Registrant (4) 4.2 Indenture related to Senior Notes, dated as of March30, 2011, between Registrant and Wells Fargo, National Association, as Trustee (4) 4.3 First Supplemental Indenture related to Senior Notes, dated as of March 30, 2011, between Registrant and Wells Fargo, National Association, as Trustee (including form of Senior Notes) (5) 4.4 Second Supplemental Indenture related to Senior Notes, dated as of December 13, 2011, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2041 Note) (6) 4.5 Third Supplemental Indenture related to Senior Notes, dated as of March 7, 2014, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2024 Note and Form of 2044 Note) (7) 4.6 Fourth Supplemental Indenture related to Senior Notes, dated as of November 17, 2014, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2025 Note and Form of 2045 Note) (8) 4.7 Fifth Supplemental Indenture, dated as of September 14, 2015, between Registrant and Wells Fargo Bank, National Association, as Trustee (including Form of 2026 Note, Form of 2035 Note and Form of 2046 Note) (9) 4.8 Sixth Supplemental Indenture, dated as of September 20, 2016, between Registrant and Wells Fargo Bank, National Association, as Trustee (including Form of 2027 Note, Form of 2036 Note and Form of 2047 Note) 10 4.9 Eighth Supplemental Indenture, dated as of September 30, 2020, between the Registrant and Wells Fargo Bank, National Association, as Trustee (including Form of 2027 Note, Form of 2030 Note, Form of 2040 Note, and Form of 2050 Note) (11) 4.10 Ninth Supplemental Indenture, dated as of September 14, 2023, between the Registrant and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as Trustee (including Form of 2033 Note and Form of 2053 Note) (12) 4.11 Description of Registrants Securities (13) 10.1* Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017 (14) 10.2* Amendment No. 1 to Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017 (15) 10.3* Gilead Sciences, Inc. 2022 Equity Incentive Plan (16) 10.4* Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018) (17) 10.5* Form ofglobalemployee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019) (18) 10.6* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019) (19) 10.7* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020) (20) 10.8* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2021) (21) 10.9* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for certain grants made in 2022) (22) 10.10* Form of global employee stock option agreement under 2022Equity Incentive Plan (4 year vest) (for certain grants made in 2022) (23) 10.11* Form of global employee stock option agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grantsmadein 2023) 10.12*,** Form of global employee stock option agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grants commencing in 2024) (24) 10.13* Form of non-employee director stock optionagreementunder2004EquityIncentivePlan(forgrantsmadein2014through2018) (17) 10.14* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grantsmadein 2019) (25) 10.15* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2020 and 2021) (22) 10.16* Form of non-employee director stock option agreement under 2022 Equity Incentive Plan (for grants made in 2022) (26) 10.17* Form of non-employee director stock option agreement under 2022 Equity Incentive Plan (for grantsmadein 2023) (19) 10.18* Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2020) (20) 10.19* Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2021) (21) 10.20* Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grantsmadein 2022) (23) 10.21* Form of performance share award agreement - TSR Goals (U.S.) under 2022 Equity Incentive Plan (for grantsmadein 2023) 10.22*,** Form of performance share award agreement - TSR Goals (U.S.) under 2022 Equity Incentive Plan (for grants commencing in 2024) (19) 10.23* Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2020) (20) 10.24* Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2021) (21) 10.25* Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grantsmadein 2022) (23) 10.26* Form of performance share award agreement - Revenue Goals (U.S.) under 2022 Equity Incentive Plan (for grantsmadein 2023) 10.27*,** Form of performance share award agreement - Revenue Goals (U.S.) under 2022 Equity Incentive Plan (for grants commencing in 2024) (17) 10.28* Form ofglobalemployee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2019) (18) 10.29* Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019) (19) 10.30* Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020) (20) 10.31* Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2021) (21) 10.32* Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for certain grants made in 2022) (22) 10.33* Form of global employee restricted stock unit agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grants made in 2022) (23) 10.34* Form of global employee restricted stock unit agreement under 2022 Equity Incentive Plan (4 year vest) (for grantsmadein 2023) 10.35*,** Form of global employee restricted stock unit agreement under 2022 Equity Incentive Plan (4 year vest) (for grants commencing in 2024) (26) 10.36* Form of non-employee director restricted stock unit agreement under 2022 Equity Incentive Plan (for grantsmadein 2023) (25) 10.37* Gilead Sciences, Inc. 2018 Equity Incentive Plan, amended and restated April 7, 2020 (27) 10.38* Gilead Sciences, Inc. Employee Stock Purchase Plan, amended and restated January 25, 2023 (17) 10.39* Gilead Sciences, Inc. 2005 Deferred Compensation Plan, amended and restated April 19, 2016 (25) 10.40* Gilead Sciences, Inc. Severance Plan, amended and restated May 5, 2020 (28) 10.41* Gilead Sciences, Inc. Corporate Annual Incentive Plan, amended and restated August 1, 2023 (29) 10.42* Offer Letter between Registrant and Daniel ODay, dated November 30, 2018 (17) 10.43* Stock option agreement for Daniel ODay under 2004 Equity Incentive Plan (17) 10.44* Form of restricted stock unit issuance agreement for Daniel ODay (in 2019) under 2004 Equity Incentive Plan (17) 10.45* Offer Letter between Registrant and Johanna Mercier, dated May 21, 2019 (19) 10.46* Global stock option agreement for Johanna Mercier (in 2019) under 2004 Equity Incentive Plan (19) 10.47* Restricted stock unit issuance agreement for Johanna Mercier (for Performance Objectives in 2019-2020) under 2004 Equity Incentive Plan (19) 10.48* Offer Letter between Registrant and Merdad Parsey, dated September 29, 2019 (19) 10.49* Global stock option agreement for Merdad Parsey (in 2019) under 2004 Equity Incentive Plan (23) 10.50* Offer Letter between Registrant and Deborah Telman, dated June 2, 2022 (23) 10.51* Global stock option agreement for Deborah Telman under 2022 Equity Incentive Plan (23) 10.52* Global restricted stock unit issuance agreement for Deborah Telman under 2022 Equity Incentive Plan (3 year vest) (23) 10.53* Global restricted stock unit issuance agreement for Deborah Telman under 2022 Equity Incentive Plan (4 year vest) (31) 10.56* Form of Employee Proprietary Information and Invention Agreement entered into between Registrant and certain of its officers and key employees (revised September2006) +(34) 10.59 Sixth Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant, dated August18, 2006, amending the October 1992 License Agreement and the December 1992 License Agreement +(35) 10.60 Seventh Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant, dated July 1, 2013, amending the October 1992 License Agreement and the December 1992 License Agreement +(37) 10.62 Royalty Sale Agreement by and among Registrant, Emory University and Investors Trust & Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, dated July18, 2005 +(37) 10.63 Amended and Restated License Agreement by and between Registrant, Emory University and Investors Trust & Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, dated July21, 2005 ++(38) 10.64 Amended and Restated EVG License Agreement by and between Japan Tobacco Inc. and Registrant, dated November 29, 2018 ++(38) 10.65 Master Agreement by and between Registrant, Gilead Sciences K.K. and Japan Tobacco Inc., dated November 29, 2018 +(39) 10.66 Amended and Restated Collaboration Agreement by and among Registrant, Gilead Sciences Ireland UC (formerly Gilead Sciences Limited) and Janssen R&D Ireland, dated December 23, 2014 +(40) 10.67 License Agreement by and among Kite Pharma, Inc., Cabaret Biotech Ltd. and Dr. Zelig Eshhar, dated December 12, 2013 ++(18) 10.68 Option, License and Collaboration Agreement by and between Galapagos NV and Registrant, dated July 14, 2019 31.1** Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended 31.2** Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended 32*** Certifications of Chief Executive Officer and Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) (41) 97.1 Gilead Sciences, Inc. Compensation Recovery Policy